Remove Manufacturing Remove Pharma Remove Safety
article thumbnail

Innovation in pharma manufacturing quality systems

European Pharmaceutical Review

As the emphasis of new drug development gravitates towards new, ground-breaking therapies and vaccines, the requirements of manufacturing sites, equipment and processes need to be appropriate for this new environment. That is because of the relative expense of emerging therapies and the pressure on pricing for continuing product lines.

article thumbnail

Brazil: untapped market for big pharma manufacturing

Pharmaceutical Technology

International companies investing in the emerging market of Brazilian pharmaceutical manufacturing will see a higher return on investment than from developed market equivalents, if they choose to compete with local manufacturers to supply Brazil’s growing market and the greater South American region.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pharma Horizons: Formulation

European Pharmaceutical Review

Inside, articles explore current vast expansion of the formulation including patient centricity, excipients, safety, quality and regulatory considerations. This Pharma Horizons report is brought to you in association with: The post Pharma Horizons: Formulation appeared first on European Pharmaceutical Review. Interested?

Pharma 59
article thumbnail

Key developments in pharmaceutical manufacturing – September 2023

European Pharmaceutical Review

September 2023 saw a wave of new pharmaceutical manufacturing facility expansions and launches across Europe. Importantly, each site features advanced technologies to support development and manufacture of these therapeutics. Materials and financing costs are high and squeezing manufacturers and their customers alike.

article thumbnail

Regeneron's high-dose Eylea hit with surprise FDA rejection over manufacturing hiccups

Fierce Pharma

But the company said it has nothing to do with the drug's efficacy or safety. | In a surprise decision, the FDA issued powerhouse Eylea's high-dose version a complete response letter.

FDA 255
article thumbnail

Pharma responds to 2024 UK General Election

European Pharmaceutical Review

This follows publication of its Manifesto , which detailed recommendations such as increasing patient access to new treatments through clinical trials and enhancing the pharmaceutical manufacturing in the UK. EU pharmacovigilance is stronger with the UK, and UK research is stronger with the EU.”

Pharma 98
article thumbnail

Advancing environmental monitoring systems for CGT manufacturing

European Pharmaceutical Review

The introduction of rapid microbiological testing methods, such as biofluorescent particle counters for real time detection of microbial contamination, has had an important impact on cell and gene therapy manufacturing. Environmental Monitoring In-Depth Focus 2024 How is eXmoor navigating these advances in the sector? What were the solution?